ABT Abbott Laboratories

XNYS Sideways Alert

Health Care

· How we analyze

About the company

Abbott Laboratories is a diversified healthcare company from Illinois. It makes medical devices such as heart products and the FreeStyle Libre glucose sensor, plus diagnostic tests, infant formula and nutrition products (Similac, Ensure) as well as generic drugs for emerging markets. As of Oct 11, 2026

Fact sheet (from the annual report) Pharmaceutical manufacturers · Abbott Park, USA

The company researches, manufactures and sells healthcare products and is divided into the segments established pharmaceuticals, diagnostics, nutrition and medical devices. The pharmaceuticals division sells branded generics in emerging markets outside the US market. The diagnostics division supplies lab systems and rapid tests to blood banks, hospitals and laboratories. Nutrition includes infant formula and products for children and adults, sold to consumers, institutions, wholesalers and retailers. The medical devices division offers devices for heart disease, glucose monitoring products for diabetes and neuromodulation for chronic pain. In November 2025 the group agreed to acquire Exact Sciences.

Automatically summarized from SEC annual report (10-K, filed Feb 20, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today +1.1%
  • 7 days +0.8%
  • 30 days +3.5%
  • 1 year −17.3%
Day range (last trading day)
−1.9%Price at 85% of the range+0.3%
52-week range
−21.8%Price at 46% of the range+25.9%
Distance from the all-time high
−26.5%

Our own calculation from the exchange’s daily candles, as of Oct 26, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Double bottom · Analysis method

This method currently detects no pattern for ABT. The check runs daily after the close.

You see new patterns immediately from Watcher, on the free plan 2 days after they form. Plans and pricing

What does the pattern show?

What is this? The price has formed two similarly deep lows and broken above the neckline between them. This is seen as a sign that the downward move is ending.

This is a calculated analysis, not a forecast and not a call to buy. Risk notice and investment advice

Load chart from TradingView

This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.

Symbol on TradingView: NYSE:ABT

Fundamental analysis

Abbott Laboratories · Sector Health Care · amounts in USD

Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Feb 20, 2026.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality Profitability, consistency, balance sheet 7 of 8 criteria met Growth Revenue and earnings per share 5 of 7 criteria met Dividend Level, consistency, coverage · 3 without data 3 of 4 criteria met Financial strength Piotroski, debt, liquidity 5 of 6 criteria met

Quality 7 of 8 met

  • met: Gross margin above 40% 56.4%
  • met: Operating margin above 15% 18.2%
  • met: Net margin above 10% 14.7%
  • not met: Return on equity above 15% 12.5%
  • met: Free cash flow margin above 10% 16.7%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 60.1%
Gross margin

56.4% Fiscal year 2025

Rank 61 of 100: higher than 61% of 153 peers (All). medium.

Rank 28 of 100: higher than 28% of 20 peers (Sector). weak.

Median Health Care: 66.6%

Share of revenue left after the direct cost of the products sold.

Operating margin

18.2% Fiscal year 2025

Rank 54 of 100: higher than 54% of 192 peers (All). medium.

Rank 53 of 100: higher than 53% of 20 peers (Sector). medium.

Median Health Care: 18.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

14.7% Fiscal year 2025

Rank 54 of 100: higher than 54% of 237 peers (All). medium.

Rank 60 of 100: higher than 60% of 26 peers (Sector). medium.

Median Health Care: 13.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

12.5% Fiscal year 2025

Rank 39 of 100: higher than 39% of 218 peers (All). medium.

Rank 36 of 100: higher than 36% of 21 peers (Sector). medium.

Median Health Care: 14.3%

Net income divided by equity at fiscal year end.

Return on assets

7.5% Fiscal year 2025 (total assets at year end)

Rank 60 of 100: higher than 60% of 238 peers (All). medium.

Rank 56 of 100: higher than 56% of 26 peers (Sector). medium.

Median Health Care: 6.4%

Net income divided by total assets at fiscal year end.

Equity ratio

60.1% Fiscal year 2025

Rank 83 of 100: higher than 83% of 239 peers (All). strong.

Rank 75 of 100: higher than 75% of 26 peers (Sector). strong.

Median Health Care: 38.5%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

16.7% Fiscal year 2025

Rank 56 of 100: higher than 56% of 213 peers (All). medium.

Rank 54 of 100: higher than 54% of 25 peers (Sector). medium.

Median Health Care: 14.9%

Free cash flow divided by revenue.

Free cash flow

7.4B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 5 of 7 met

  • not met: Over 3 years, revenue grew by more than 5% per year +0.5%
  • met: Over 5 years, revenue grew by more than 5% per year +5.1%
  • met: Over 10 years, revenue grew by more than 5% per year +8.1%
  • not met: Over 3 years, EPS grew by more than 5% per year −1.6%
  • met: Over 5 years, EPS grew by more than 5% per year +8.3%
  • met: Revenue rose in at least 4 of the last 5 fiscal years 4 of 5
  • met: Revenue rose in the last fiscal year +5.7%
Revenue growth 3 years

+0.5% per year

Rank 19 of 100: higher than 19% of 230 peers (All). weak.

Rank 26 of 100: higher than 26% of 25 peers (Sector). weak.

Median Health Care: +5.6%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+5.1% per year

Rank 20 of 100: higher than 20% of 217 peers (All). weak.

Rank 22 of 100: higher than 22% of 25 peers (Sector). weak.

Median Health Care: +8.5%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+8.1% per year

Rank 56 of 100: higher than 56% of 157 peers (All). medium.

Rank 29 of 100: higher than 29% of 19 peers (Sector). weak.

Median Health Care: +10.1%

Average growth per year over 10 fiscal years.

EPS growth 3 years

−1.6% per year

Rank 22 of 100: higher than 22% of 157 peers (All). weak.

Rank 25 of 100: higher than 25% of 22 peers (Sector). weak.

Median Health Care: +5.5%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

+8.3% per year

Rank 33 of 100: higher than 33% of 146 peers (All). medium.

Rank 58 of 100: higher than 58% of 20 peers (Sector). medium.

Median Health Care: +7.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+2.5% per year

Rank 17 of 100: higher than 17% of 140 peers (All). weak.

Rank 28 of 100: higher than 28% of 20 peers (Sector). weak.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 3 of 4 met · 3 without data

  • met: Pays a dividend 2.40 USD
  • not met: Payout ratio at most 60% of earnings 65%
  • no data: Dividend paid in each of the last 5 fiscal years not reported as an annual figure for each of the last 5 fiscal years
  • no data: Dividend per share never lowered in the last 5 fiscal years not reported as an annual figure for each of the last 5 fiscal years
  • no data: Dividend per share higher than 5 years ago no comparable dividend 5 years ago
  • met: Free cash flow per share covers the dividend 1.8x
  • met: Dividends paid over the last 5 years covered by free cash flow 51% of free cash flow
Payout ratio

65% Fiscal year 2025

Dividend per share divided by earnings per share.

Free cash flow coverage

1.8x Fiscal year 2025

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 5 of 6 met

  • not met: Piotroski F-Score at least 7 of 9 6 of 9
  • met: Long-term debt no higher than equity 0.25
  • met: Current assets cover current liabilities 1.58
  • met: Positive equity 52.1B USD
  • met: In 5 years, share count up by at most 5% −2.1%
  • met: Free cash flow positive in the last fiscal year 7.4B USD
Piotroski F-Score

6 of 9 Fiscal year 2025

Rank 45 of 100: higher than 45% of 134 peers (All). medium.

Rank 32 of 100: higher than 32% of 19 peers (Sector). weak.

Median Health Care: 7.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.25 at fiscal year end

Rank 76 of 100: lower than 76% of 199 peers (All). strong.

Rank 86 of 100: lower than 86% of 18 peers (Sector). strong.

Median Health Care: 0.72

Long-term financial debt divided by equity.

Liquidity (current ratio)

1.58 at fiscal year end

Rank 56 of 100: higher than 56% of 215 peers (All). medium.

Rank 52 of 100: higher than 52% of 26 peers (Sector). medium.

Median Health Care: 1.56

Current assets divided by current liabilities.

Change in share count

−2.1% in 5 years

Rank 53 of 100: lower than 53% of 199 peers (All). medium.

Rank 48 of 100: lower than 48% of 24 peers (Sector). medium.

Median Health Care: −2.7%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • not met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • met: Long-term debt relative to total assets fell
  • not met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • met: Gross margin higher than the prior year
  • not met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light yellow: Revenue grew over 5 years (+5.1% per year), more slowly than the sector median.
  • Light green: Net income (total) grew over 5 years (+7.7% per year), at least as fast as the sector median; per share +8.3% per year.
  • Light green: Net margin 14.7%, above the sector median (12.9%).
  • Light green: Debt not higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.
  • Light yellow: High payout ratio (65% of earnings).

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 20.9B USD · Net income 1.4B USD · Net margin 6.7%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 27.4B USD · Net income 477.0M USD · Net margin 1.7%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 30.6B USD · Net income 2.4B USD · Net margin 7.7%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 31.9B USD · Net income 3.7B USD · Net margin 11.6%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 34.6B USD · Net income 4.5B USD · Net margin 13.0%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 43.1B USD · Net income 7.1B USD · Net margin 16.4%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 43.7B USD · Net income 6.9B USD · Net margin 15.9%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 40.1B USD · Net income 5.7B USD · Net margin 14.3%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 42.0B USD · Net income 13.4B USD · Net margin 31.9%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 44.3B USD · Net income 6.5B USD · Net margin 14.7%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 44.3B USD · Net income 6.5B USD · Net margin 14.7%

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 56.4 USD gross profit, 18.2 USD operating income and 14.7 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue44.3B USD100.0%
Gross profit25.0B USD56.4%
Cost of revenue19.3B USD43.6%
Operating income8.1B USD18.2%
Research & development2.9B USD6.6%
Other operating expenses14.0B USD31.6%
Net income6.5B USD14.7%
Interest expense493.0M USD1.1%
Taxes & other (net)1.0B USD2.3%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin rose in 5 years from 15.5% to 18.2%.

Gross marginOperating marginNet margin
  1. Fiscal year 2016: Gross margin 56.4% · Operating margin 15.3% · Net margin 6.7%
  2. Fiscal year 2017: Gross margin 54.7% · Operating margin 6.3% · Net margin 1.7%
  3. Fiscal year 2018: Gross margin 58.4% · Operating margin 11.9% · Net margin 7.7%
  4. Fiscal year 2019: Gross margin 58.5% · Operating margin 14.2% · Net margin 11.6%
  5. Fiscal year 2020: Gross margin 56.6% · Operating margin 15.5% · Net margin 13.0%
  6. Fiscal year 2021: Gross margin 57.0% · Operating margin 19.6% · Net margin 16.4%
  7. Fiscal year 2022: Gross margin 56.1% · Operating margin 19.2% · Net margin 15.9%
  8. Fiscal year 2023: Gross margin 55.2% · Operating margin 16.2% · Net margin 14.3%
  9. Fiscal year 2024: Gross margin 55.4% · Operating margin 16.3% · Net margin 31.9%
  10. Fiscal year 2025: Gross margin 56.4% · Operating margin 18.2% · Net margin 14.7%

Returns

Return on equity fell in 5 years from 13.7% to 12.5%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 6.8% · Return on assets 2.7%
  2. Fiscal year 2017: Return on equity 1.5% · Return on assets 0.6%
  3. Fiscal year 2018: Return on equity 7.8% · Return on assets 3.5%
  4. Fiscal year 2019: Return on equity 11.9% · Return on assets 5.4%
  5. Fiscal year 2020: Return on equity 13.7% · Return on assets 6.2%
  6. Fiscal year 2021: Return on equity 19.8% · Return on assets 9.4%
  7. Fiscal year 2022: Return on equity 18.9% · Return on assets 9.3%
  8. Fiscal year 2023: Return on equity 14.8% · Return on assets 7.8%
  9. Fiscal year 2024: Return on equity 28.1% · Return on assets 16.5%
  10. Fiscal year 2025: Return on equity 12.5% · Return on assets 7.5%

Equity and long-term debt

The equity ratio rose in 5 years from 45.2% to 60.1%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 20.5B USD · Long-term debt 20.7B USD
  2. Fiscal year 2017: Equity 30.9B USD · Long-term debt 27.7B USD
  3. Fiscal year 2018: Equity 30.5B USD · Long-term debt 19.4B USD
  4. Fiscal year 2019: Equity 31.1B USD · Long-term debt 17.9B USD
  5. Fiscal year 2020: Equity 32.8B USD · Long-term debt 18.5B USD
  6. Fiscal year 2021: Equity 35.8B USD · Long-term debt 18.1B USD
  7. Fiscal year 2022: Equity 36.7B USD · Long-term debt 16.8B USD
  8. Fiscal year 2023: Equity 38.6B USD · Long-term debt 14.7B USD
  9. Fiscal year 2024: Equity 47.7B USD · Long-term debt 14.1B USD
  10. Fiscal year 2025: Equity 52.1B USD · Long-term debt 12.9B USD

Liquidity (current ratio)

The current ratio fell in 5 years from 1.72 to 1.58.

Current ratio
  1. Fiscal year 2016: Current ratio 4.02
  2. Fiscal year 2017: Current ratio 2.26
  3. Fiscal year 2018: Current ratio 1.62
  4. Fiscal year 2019: Current ratio 1.44
  5. Fiscal year 2020: Current ratio 1.72
  6. Fiscal year 2021: Current ratio 1.85
  7. Fiscal year 2022: Current ratio 1.63
  8. Fiscal year 2023: Current ratio 1.64
  9. Fiscal year 2024: Current ratio 1.67
  10. Fiscal year 2025: Current ratio 1.58

Cash flow

Free cash flow rose in 5 years from 5.7B USD to 7.4B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 3.2B USD · Capital expenditure 1.1B USD · Free cash flow 2.1B USD
  2. Fiscal year 2017: Operating cash flow 5.6B USD · Capital expenditure 1.1B USD · Free cash flow 4.4B USD
  3. Fiscal year 2018: Operating cash flow 6.3B USD · Capital expenditure 1.4B USD · Free cash flow 4.9B USD
  4. Fiscal year 2019: Operating cash flow 6.1B USD · Capital expenditure 1.6B USD · Free cash flow 4.5B USD
  5. Fiscal year 2020: Operating cash flow 7.9B USD · Capital expenditure 2.2B USD · Free cash flow 5.7B USD
  6. Fiscal year 2021: Operating cash flow 10.5B USD · Capital expenditure 1.9B USD · Free cash flow 8.6B USD
  7. Fiscal year 2022: Operating cash flow 9.6B USD · Capital expenditure 1.8B USD · Free cash flow 7.8B USD
  8. Fiscal year 2023: Operating cash flow 7.3B USD · Capital expenditure 2.2B USD · Free cash flow 5.1B USD
  9. Fiscal year 2024: Operating cash flow 8.6B USD · Capital expenditure 2.2B USD · Free cash flow 6.4B USD
  10. Fiscal year 2025: Operating cash flow 9.6B USD · Capital expenditure 2.2B USD · Free cash flow 7.4B USD

Share count

The share count fell in 5 years by 2.1% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 1.5B
  2. Fiscal year 2017: Diluted share count 1.7B
  3. Fiscal year 2018: Diluted share count 1.8B
  4. Fiscal year 2019: Diluted share count 1.8B
  5. Fiscal year 2020: Diluted share count 1.8B
  6. Fiscal year 2021: Diluted share count 1.8B
  7. Fiscal year 2022: Diluted share count 1.8B
  8. Fiscal year 2023: Diluted share count 1.7B
  9. Fiscal year 2024: Diluted share count 1.7B
  10. Fiscal year 2025: Diluted share count 1.7B

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
2.40 USD · Fiscal year 2025
Dividend growth per year
3 y +7.7%5 y –10 y –
Years without a cut
at least 3 as far as the data goes
Payout ratio
of earnings 65% of free cash flow 56%
To shareholders (5 years)
27.5B USD 35% through repurchases
Share count over 5 years
−2.1% fewer shares – each share is a larger stake

Dividend per share

The dividend per share rose in 3 years from 1.92 USD to 2.40 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share not available
  2. Fiscal year 2017: Dividend per share not available
  3. Fiscal year 2018: Dividend per share not available
  4. Fiscal year 2019: Dividend per share not available
  5. Fiscal year 2020: Dividend per share not available
  6. Fiscal year 2021: Dividend per share not available
  7. Fiscal year 2022: Dividend per share 1.92 USD
  8. Fiscal year 2023: Dividend per share 2.08 USD
  9. Fiscal year 2024: Dividend per share 2.24 USD
  10. Fiscal year 2025: Dividend per share 2.40 USD

Payout ratios

The payout ratio rose in 3 years from 49.1% to 64.5%.

Payout ratio (earnings)Payout ratio (free cash flow)
  1. Fiscal year 2016: Payout ratio (earnings) not available · Payout ratio (free cash flow) 73.9%
  2. Fiscal year 2017: Payout ratio (earnings) not available · Payout ratio (free cash flow) 41.7%
  3. Fiscal year 2018: Payout ratio (earnings) not available · Payout ratio (free cash flow) 40.2%
  4. Fiscal year 2019: Payout ratio (earnings) not available · Payout ratio (free cash flow) 50.5%
  5. Fiscal year 2020: Payout ratio (earnings) not available · Payout ratio (free cash flow) 44.7%
  6. Fiscal year 2021: Payout ratio (earnings) not available · Payout ratio (free cash flow) 37.0%
  7. Fiscal year 2022: Payout ratio (earnings) 49.1% · Payout ratio (free cash flow) 42.4%
  8. Fiscal year 2023: Payout ratio (earnings) 63.8% · Payout ratio (free cash flow) 70.3%
  9. Fiscal year 2024: Payout ratio (earnings) 29.3% · Payout ratio (free cash flow) 60.4%
  10. Fiscal year 2025: Payout ratio (earnings) 64.5% · Payout ratio (free cash flow) 55.7%

What goes back to shareholders

Over 5 years, 27.5B USD went back to shareholders, 35% of it through share repurchases. That is 78% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid 1.5B USD · Share repurchases 522.0M USD · New shares issued (including employee plans) not available · Free cash flow 2.1B USD
  2. Fiscal year 2017: Dividends paid 1.8B USD · Share repurchases 117.0M USD · New shares issued (including employee plans) not available · Free cash flow 4.4B USD
  3. Fiscal year 2018: Dividends paid 2.0B USD · Share repurchases 238.0M USD · New shares issued (including employee plans) not available · Free cash flow 4.9B USD
  4. Fiscal year 2019: Dividends paid 2.3B USD · Share repurchases 718.0M USD · New shares issued (including employee plans) not available · Free cash flow 4.5B USD
  5. Fiscal year 2020: Dividends paid 2.6B USD · Share repurchases 403.0M USD · New shares issued (including employee plans) not available · Free cash flow 5.7B USD
  6. Fiscal year 2021: Dividends paid 3.2B USD · Share repurchases 2.3B USD · New shares issued (including employee plans) not available · Free cash flow 8.6B USD
  7. Fiscal year 2022: Dividends paid 3.3B USD · Share repurchases 3.8B USD · New shares issued (including employee plans) not available · Free cash flow 7.8B USD
  8. Fiscal year 2023: Dividends paid 3.6B USD · Share repurchases 1.2B USD · New shares issued (including employee plans) not available · Free cash flow 5.1B USD
  9. Fiscal year 2024: Dividends paid 3.8B USD · Share repurchases 1.3B USD · New shares issued (including employee plans) not available · Free cash flow 6.4B USD
  10. Fiscal year 2025: Dividends paid 4.1B USD · Share repurchases 893.0M USD · New shares issued (including employee plans) not available · Free cash flow 7.4B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Abbott Laboratories next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison ABT, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
LLY Lilly (Eli) 65.2B USD +21.6%83.0%–31.7%77.8%23.6%13.8%7/9
MRK Merck & Co. 65.0B USD +6.3%74.8%–28.1%34.7%38.4%19.0%4/9
PFE Pfizer 62.6B USD +8.5%74.3%–12.4%9.0%41.5%14.5%6/9
ABBV AbbVie 61.2B USD +6.0%70.2%24.6%6.9%–−2.4%29.1%8/9
BMY Bristol Myers Squibb 48.2B USD +2.5%71.1%–14.6%38.2%20.5%26.7%8/9
TMO Thermo Fisher Scientific 44.6B USD +6.7%–17.4%15.0%12.6%48.4%14.1%–
ABT Abbott Laboratories this stock 44.3B USD +5.1%56.4%18.2%14.7%12.5%60.1%16.7%6/9
AMGN Amgen 36.8B USD +7.6%67.2%24.7%21.0%89.1%9.6%22.0%7/9
MDT Medtronic 36.4B USD +3.8%65.0%17.8%13.2%9.7%53.2%14.9%7/9
Median of the sector 26 symbols 44.4B USD +8.5%66.6%18.0%13.9%14.3%38.5%14.9%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Figures of the last fiscal year from SEC annual reports (peers as of Oct 28, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+5.1% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 5.1% per year on average, but more slowly than the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light green: above sector

+7.7% per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: +8.3% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 7.7% per year on average – at least as fast as the median company in the sector (+7.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

14.7% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 14.72 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was 13.0%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light green: lower than sector

0.57 latest balance sheet

Sector Health Care: median 0.66 (49 symbols)

What does this mean? For every 1 USD of equity there is 0.57 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light yellow: high

65% Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.65 USD went to shareholders as a dividend. Little buffer remains for weaker years. Median company in the sector: 28%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
44.3B USD
Revenue vs. prior year
+5.7%
Net income (FY)
6.5B USD
Net income vs. prior year
−51.3%
EPS (FY)
3.72 USD
13F funds with a position
2 of 9
Funds vs. prior quarter
+1
Shares held vs. prior quarter
+599.5%
Fiscal year to Dec 31, 2025 · 10-K filed Feb 20, 2026 · Balance sheet Mar 31, 2026 (filed Apr 29, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 44.3B6.5B 14.7% 3.72 2.40 65%
2024Dec 31, 2024 42.0B13.4B 31.9% 7.64 2.24 29%
2023Dec 31, 2023 40.1B5.7B 14.3% 3.26 2.08 64%
2022Dec 31, 2022 43.7B6.9B 15.9% 3.91 1.92 49%
2021Dec 31, 2021 43.1B7.1B 16.4% 3.94 – –
2020Dec 31, 2020 34.6B4.5B 13.0% 2.50 – –
2019Dec 31, 2019 31.9B3.7B 11.6% 2.06 – –
2018Dec 31, 2018 30.6B2.4B 7.7% 1.33 – –
2017Dec 31, 2017 27.4B477.0M 1.7% 0.27 – –
2016Dec 31, 2016 20.9B1.4B 6.7% 0.94 – –
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q1/26Mar 31, 2026 11.2B1.1B 9.6% 0.61 0.63 103%
Q4/25*Dec 31, 2025 11.5B1.8B 15.5% – 0.63 –
Q3/25Sep 30, 2025 11.4B1.6B 14.5% 0.94 0.59 63%
Q2/25Jun 30, 2025 11.1B1.8B 16.0% 1.01 0.59 58%
Q1/25Mar 31, 2025 10.4B1.3B 12.8% 0.76 0.59 78%
Q4/24*Dec 31, 2024 11.0B9.2B 84.1% – 0.59 –
Q3/24Sep 30, 2024 10.6B1.6B 15.5% 0.94 0.55 59%
Q2/24Jun 30, 2024 10.4B1.3B 12.5% 0.74 0.55 74%
Q1/24Mar 31, 2024 10.0B1.2B 12.3% 0.70 0.55 79%
Q4/23*Dec 31, 2023 10.2B1.6B 15.6% – 0.55 –
Q3/23Sep 30, 2023 10.1B1.4B 14.2% 0.82 0.51 62%
Q2/23Jun 30, 2023 10.0B1.4B 13.8% 0.78 – –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $46.9M3 people −$46.9M
6 months $173.6K1 person $46.9M3 people −$46.7M
12 months $4.4M4 people $47.5M7 people −$43.1M

Latest transactions

  • Sep 2, 2026 Mccoy John A. Jr. Officer Open-market sale 27 shares · $3.0K · SEC
  • Aug 25, 2026 Ford Robert B Chief executive (CEO), Director Open-market sale 180,297 shares · $20.9M · SEC
  • Aug 25, 2026 Ford Robert B Chief executive (CEO), Director Open-market sale 218,535 shares · $25.3M · SEC
  • Aug 11, 2026 Morrone Louis H. Officer Open-market sale 5,850 shares · $642.5K · SEC
  • May 7, 2026 Stratton John G Director Open-market purchase 2,000 shares · $173.6K · SEC
  • Apr 27, 2026 Starks Daniel J Director Open-market purchase 10,000 shares · $926.5K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score -25

Price vs. EMA 50+15
Price vs. EMA 200-15
EMA 50 vs. EMA 200-20
ADX (trend strength)+0
Highs and lows+10
Relative strength-15

Volatility and trend strength

ADX 14 (trend strength)20.3
Rel. strength 60 d−3.2%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on ABT yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: ABT

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

Log in Sign up free

↑ ↓ select · Enter open · Esc close